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The diverse physiological roles of the neurotrophin family have
long prompted exploration of their potential as therapeutic agents
for nerve injury and neurodegenerative diseases. To date, clinical
trials of one family member, brain-derived neurotrophic factor
(BDNF), have disappointingly failed to meet desired endpoints.
Contributing to these failures is the fact that BDNF is pharmaceu-
tically a nonideal biologic drug candidate. It is a highly charged, yet
is a net hydrophobic molecule with a low molecular weight that
confers a short t1/2 in man. To circumvent these shortcomings of
BDNF as a drug candidate, we have employed a function-based
cellular screening assay to select activating antibodies of the BDNF
receptor TrkB from a combinatorial human short-chain variable frag-
ment antibody library. We report here the successful selection of
several potent TrkB agonist antibodies and detailed biochemical and
physiological characterization of one such antibody, ZEB85. By using
a human TrkB reporter cell line and BDNF-responsive GABAergic
neurons derived from human ES cells, we demonstrate that ZEB85
is a full agonist of TrkB, comparable in potency to BDNF toward
human neurons in activation of TrkB phosphorylation, canonical
signal transduction, and mRNA transcriptional regulation.
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Extensive studies, including gene-KO analyses, have demon-strated a pivotal role of neurotrophic factors in sculpting the
nervous system during mammalian development (1). In the adult
nervous system, additional roles of these protein growth factors
have been identified as regulators of synaptic plasticity and neu-
rotransmitter phenotypes. Among such factors are the neuro-
trophins: nerve growth factor (NGF), brain-derived neurotrophic
factor (BDNF), and neurotrophin (NT)3 and NT4. Since the
discovery that NGF and BDNF, in addition to actions upon pe-
ripheral sympathetic and sensory neurons, regulate the neuro-
transmitter phenotype of basal forebrain cholinergic neurons,
there has been great interest in exploring the potential of neuro-
trophin family members as therapeutic agents in nerve injury and
neurodegenerative diseases. As a comprehensive understanding of
the biological role of BDNF has emerged, potential therapeutic
utility has extended to neurological conditions such as Alzheimer’s,
Parkinson’s, and Huntington’s diseases, as well as retinal diseases
and hearing disorders (2). In addition to the knowledge accumu-
lated by using animal models, genetic data strongly support the
relevance of BDNF in humans. For example, an SNP in the BDNF
gene has been linked to mild memory impairment (3), and loss-
of-allele mutations in NTRK2 and BDNF have been linked to
severe developmental defects and obesity (4, 5). Also, NT4 mu-
tations have been associated with rare cases of glaucoma (6, 7).
Based on studies demonstrating survival-promoting effects of
BDNF on cultured motor neurons (8), the ability of locally applied
BDNF to prevent atrophy/loss of axotomized facial nerve motor
neurons in neonatal mice and the ameliorating effects of s.c.-injected
BDNF in genetic models of motor neuron atrophy (9), BDNF
was advanced to randomized, double-blinded phase III clinical
trials in amyotrophic lateral sclerosis (ALS). Disappointingly, s.c.
administration of BDNF in patients with ALS failed to meet
primary endpoints of improved lung function and overall survival
(10), despite positive efficacy trends in smaller phase II studies.
To circumvent possible limited access of s.c.-administered BDNF
to the cell body of motor neurons within the spinal cord, small
trials were also undertaken with direct intrathecal infusions of
BDNF (11), but these studies also did not convincingly demon-
strate any benefits to patients. These trials were conducted
knowing that BDNF is not an ideal biologic drug candidate,
given its high net charge (pI of ∼9.6) and propensity to adhere to
glass and plastic surfaces, requiring complex drug formulation
with excipients. Further, and most relevant for systemic routes of
administration for diseases such as ALS, the relatively small
protein molecular mass (27 kDa) of BDNF confers only a short
serum t1/2 in man. Additionally, when delivered directly to the
Significance
Neurotrophin receptors are a class of receptor tyrosine kinases
that couple to signaling pathways critical for neuronal survival
and growth. One member, TrkB, is particularly interesting be-
cause it plays a role in many severe degenerative neurological
diseases. The TrkB natural ligand brain-derived neurotrophic
factor (BDNF) is not suitable to be developed as a drug or ther-
apy as proved by previous unsuccessful clinical trials. Here we
report a selection method that produced potent full agonist
antibodies that mimic BDNF function, yet with better biophysical
properties. This study paves the road for the development of
agonist antibodies for other receptor tyrosine kinases.
Author contributions: S.M., Y.-A.B., M.L., P.S.D., R.M.L., R.A.L., and J.X. designed research;
S.M., K.E.B., N.D.A., A.V.S., N.C.W., G.G., C.-W.L., X.N., P.C.-F., and J.X. performed research;
R.M.L. and R.A.L. contributed new reagents/analytic tools; S.M., Y.-A.B., K.E.B., A.V.S.,
N.C.W., G.G., C.-W.L., M.L., X.N., P.C.-F., P.S.D., R.M.L., R.A.L., and J.X. analyzed data;
and S.M., Y.-A.B., K.E.B., N.C.W., P.S.D., R.M.L., R.A.L., and J.X. wrote the paper.
Reviewers: M.V.C., Skirball Institute of Biomolecular Medicine; and T.H., Karolinska
Institutet.
Conflict of interest statement: This work was supported by Zebra Biologics. P.S.D. and
R.M.L. are affiliated with Zebra Biologics.
This open access article is distributed under Creative Commons Attribution-NonCommercial-
NoDerivatives License 4.0 (CC BY-NC-ND).
Data deposition: Next-generation sequencing data related to this study have been up-
loaded in ArrayExpress (accession no. E-MTAB-6975).
1Present address: Private address, Melrose Street, Belfast BT9 7DN, United Kingdom.
2Present address: Hospital Universitario Virgen Macarena, University of Seville, E41009
Seville, Spain.
3To whom correspondence may be addressed. Email: rlerner@scripps.edu or jiaxie@
scripps.edu.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1806660115/-/DCSupplemental.
www.pnas.org/cgi/doi/10.1073/pnas.1806660115 PNAS Latest Articles | 1 of 10
A
PP
LI
ED
BI
O
LO
G
IC
A
L
SC
IE
N
CE
S
CNS by intraventricular or intrathecal routes, BDNF, unlike
NGF, diffuses very poorly across the ependymal layer of the
ventricular lining (12). Diffusion within the CNS is equally lim-
ited when BDNF is infused directly into brain parenchyma (13).
Possible approaches to circumventing the poor drug-like proper-
ties of the BDNF protein itself include (i) development of highly
selective small-molecule or peptide agonists of TrkB, the tyrosine
kinase receptor activated by BDNF and NT4 (14–17); or (ii) de-
veloping molecules that up-regulate the endogenous levels of BDNF
expression at selective sites or in specific neuronal types within the
CNS (18–20). Although a number of studies have reported the dis-
covery of small-molecule mimetics of BDNF that act as TrkB ago-
nists, two recent independent studies have cast doubt on the
usefulness of such reagents (17, 21). Alternatively, several reports
have demonstrated that it is feasible through conventional hybridoma
techniques to select TrkB-activating antibodies from mice immu-
nized with TrkB ectodomain protein (22, 23). Although a few
studies have reported modest efficacy of TrkB-activating antibodies
in animal models (24, 25), there has been only limited character-
ization of the actions of these TrkB agonist antibodies on highly
enriched human neurons, and their clinical potential is uncertain.
With the intention of reinvestigating the clinical potential of
neurotrophin receptor agonists in neural compartments such as the
retina and the inner ear, we have taken advantage of a function-
based screening technology to allow discovery of Trk receptor ag-
onist antibodies from large combinatorial libraries of human short-
chain variable fragment (scFv) antibodies (26, 27). We report here
the successful selection of several TrkB-agonist antibodies, the first
application of our function-based screening platform to a member
of the large receptor tyrosine kinase family. The TrkB-activating
agonist antibodies we have identified range from full to partial
agonists in our reporter cell assay. We characterized the most po-
tent of these antibodies (ZEB85) on highly enriched cultures of
BDNF-responsive GABAergic neurons derived from human ES
(hES) cells (28–30). We describe here the selection methodology
and detailed characterization of ZEB85 in the format of an scFv–Fc
fusion protein antibody. We show that ZEB85 is a full agonist of
TrkB with a potency and activity similar to that of BDNF.
Results
Reporter Cell Line.We have previously established technology that
allows the direct function-based screening of large combinatorial
antibody or peptide libraries to discover agonist antibodies or
agonist peptides to cell-surface receptors, such as G protein-
coupled receptors and cytokine receptors (26, 27, 31). In the
present study, we have applied this technology to generate fully
human agonist antibodies to the receptor tyrosine kinase TrkB.
In its most effective form, the selection protocol is a two-step
process: generation of a highly sensitive TrkB reporter cell line
and phage scFv library panning of the TrkB ectodomain. Two
independent TrkB reporter cell lines were constructed. An
HEK293 and a CHO cell line were separately infected with a
lentiviral vector encoding the full-length human NTRK2 gene
under the EF1a promoter. The HEK293 cells were also infected
with a lentiviral vector encoding the β-lactamase protein regu-
lated by a CRE response element, whereas the CHO cells were
infected with the β-lactamase gene expression regulated by an
NFAT response element (Fig. 1A). From pilot experiments, we
determined that only a narrow range of TrkB receptor expres-
sion permitted the generation of high signal-to-noise reporter
cell lines. Overly high cell-surface expression resulted in TrkB
kinase domain autophosphorylation and thus ligand independent
activation of the reporter readout, somewhat typical when re-
ceptor tyrosine kinases are overexpressed. Conversely, under-
expression of TrkB resulted in an inadequate fluorescent signal
to enable cell sorting. As our screening system relies on FACS,
high background gives way to a high false-positive rate with
overall low selection efficiency. This is particularly problematic
when selecting for rare agonist antibodies in the library. When
expressed within the optimal range, ligand stimulation of TrkB in
the reporter cell results in activation of canonical signals that in-
duce expression of the β-lactamase reporter construct; in turn,
addition of a β-lactamase FRET pair substrate results in its
cleavage and emission of a fluorescent signal (Fig. 1D). When they
had been grown up as stable cell lines, both the hTrkB–CRE–
β-lactamase line and the hTrkB–NFAT–β-lactamase lines showed
high signal-to-noise ratios when treated with 10 nM BDNF.
As assessed by flow cytometry, the TrkB (CHO-NFAT) re-
porter cell line was shown to bind BDNF but not NGF (Fig. 1C).
This TrkB reporter cell line also bound NT3 and NT4, known
ligands of this receptor (Fig. 1C). Similarly, as shown in Fig. 1B,
the TrkB reporter cell line was activated by BDNF, NT3, and
NT4, but not NGF, confirming that the cell line behaved as
expected for binding and functional response to TrkB agonists. A
TrkA reporter cell line generated in a similar fashion for the
purpose of selectivity screening was shown to selectively bind
NGF but not BDNF (SI Appendix, Fig. S1A). This TrkA cell line
was activated by NGF but not by BDNF (SI Appendix, Fig. S1B).
Nontransfected HEK293 or CHO cells did not respond to any of
the neurotrophins (SI Appendix, Fig. S1C). Collectively, these
results show that the TrkB reporter cell lines complied with the
binding and activation properties expected for TrkB and dem-
onstrate the high signal-to-noise ratio necessary for the high-
capacity function-based antibody selection procedure used here.
Panning of Human TrkB Ectodomain. In the second step of candi-
date agonist antibody selection, the ectodomain protein of
hTrkB was “panned” with a large (>1010) combinatorial scFv
antibody library expressed in phage, as described previously (27)
and as outlined in the scheme in SI Appendix, Fig. S2. The
binders or “hits” (∼106) were cloned into a lentiviral vector that
encodes a transmembrane domain and an Ig Fc domain in tan-
dem with each of the unique scFv panning hit sequences, such
that, when expressed in individual cells, each scFv protein is
tethered to the extracellular side of the plasma membrane as an
Fc-dimer. The virus was titered and infected into a single plate
(1–2 × 107 cells) of the HEK293-CRE or CHO-NFAT TrkB
reporter cell lines. We targeted lentiviral infection to a multi-
plicity of infection of ∼2. In this manner, each cell in the plate
becomes an independent autocrine assay point. The scheme in
Fig. 1D illustrates the selection system in the reporter cell line:
when a given surface-expressed (i.e., tethered) scFv fragment
activates the TrkB receptor, a fluorescent signal is generated and
those cells are selected by FACS. To enrich for resulting hits,
antibody genes from positive-signal cells were subcloned back
into the lentiviral vector and reinfected into fresh reporter cells.
After three rounds of this enrichment, selected clones were
prepared as scFv–Fc constructs and expressed as proteins in
HEK293 cells. Following purification, these hits were assayed in
the reporter cell line to verify agonist activity.
Antibody Selection and Characterization. By using the HEK293-
CRE and the CHO-NFAT TrkB reporter cell lines, we identified
a total of ∼50 active clones from our function-based screening
assay. DNA sequencing of these scFv antibody fragments
revealed some antibodies that were closely related in sequence to
each other, whereas others were quite disparate (SI Appendix,
Fig. S3). We selected 10 of the more active clones with distinct
sequences for further study. These were expressed as scFv–Fc
fusion protein constructs for initial activity assessment in the
CHO-NFAT TrkB reporter cell line. Fig. 2A shows that several
potent scFv–Fc agonist antibodies were identified with EC50
values ranging from 0.5 nM to 20 nM, compared with BDNF
with an EC50 of 0.3 nM. In addition, some antibodies appeared
to be full agonists (ZEB85, ZEB30) compared with BDNF,
whereas others (ZEB44, ZEB27) showed partial agonism with
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Emax (agonist maximum response) values 10–60% that of BDNF.
By using flow cytometry, antibodies ZEB30 and ZEB85 were
also shown to bind to the TrkB reporter cell line (Fig. 2B).
The activity profile of ZEB85 in the human TrkB reporter cell
line suggests that it possesses full agonist activity, raising the
question whether this particular antibody binds to the native ag-
onist site on TrkB. To test this, we used flow cytometry to de-
termine whether neurotrophins could compete for binding of
ZEB85 to TrkB reporter cells. ZEB85 efficiently bound TrkB cells
over a range of concentrations, and 0.25 μg/mL (2.3 nM) was used
for neurotrophin displacement studies. A 4- and 12-fold molar
excess of BDNF reduced binding of ZEB85 by 80% and 89%,
respectively (SI Appendix, Fig. S4). Binding was also reduced by
NT4, and NT3 to a slightly lesser extent, whereas NGF had no
effect (SI Appendix, Fig. S4), consistent with TrkB pharmacology.
These results suggest that ZEB85 binds at, or very near, the
BDNF agonist site on TrkB.
To determine selectivity toward TrkB, we assayed the anti-
bodies in the TrkA reporter cell line. In contrast to NGF, none of
the 10 TrkB-activating scFv–Fc antibodies showed any activation
of the TrkA reporter cells (Fig. 2C). TrkB antibody selectivity was
also demonstrated by examining ectodomain binding. Analyses of
Western blots showed that our TrkB agonist antibodies recognized
human TrkB ectodomain but not that of TrkA or TrkC, nor the
low-affinity neurotrophin receptor p75 (Fig. 2D). As controls,
commercial antibodies (SI Appendix, Methods S1) specific for
TrkA, TrkC, and p75 recognized their respective ectodomains on
these filters. To demonstrate that the TrkB agonist antibodies
were capable of canonical signaling similar to that of BDNF, the
CHO-NFAT TrkB reporter cell line was exposed to antibodies
ZEB85, ZEB44, ZEB30, and ZEB27 for 5 or 30 min, and Western
blots prepared from these cell lysates were probed for total and
phosphorylated PLCγ, AKT, and MAPK. As with BDNF, all of
the antibodies stimulated canonical signaling; however, subtle
differences in magnitude and time course were evident, consistent
with differences seen in quantitative activation (Fig. 2E). Taken
together, the results from Fig. 2 demonstrate that our methodol-
ogy of autocrine selection of agonist antibodies from large com-
binatorial libraries was able to identify an array of potent and
selective TrkB agonist antibodies that behave similarly to BDNF
in terms of binding and signal transduction. From a technical
perspective, we have shown this to be a flexible system, in that
TrkB activating antibodies were successfully selected by using an
HEK293 cell with a CRE reporter construct or a CHO cell with an
NFAT reporter construct as host cells for the hTrkB receptor. It is
important to highlight that our function-based selection assay is
greatly facilitated in terms of high capacity and ease of use in that all
manipulations to generate hits are carried out at the DNA level;
only at the endpoint of advancing candidates was protein pro-
duction and purification necessary to further validate TrkB acti-
vating antibodies. Furthermore, this DNA-based, high-throughput
selection capacity allows rapid generation and screening of millions
of variants to optimize activity, affinity, stability, and expression of
a given antibody.
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Fig. 1. Reporter cell line construction and characterization. (A) Design of exogenously transduced lentiviral constructs for the reporter cell lines. (B) Con-
centration–response curves of different ligands on the TrkB reporter line (NFAT). (C) Flow cytometry analysis of the TrkB reporter cell line (NFAT) activation
when treated with different ligands. (D) Illustration of the reporter mechanism when activated.
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Characterization of ZEB85 on Human Neurons. To examine the intrinsic
effects of TrkB-activating antibodies on human neurons, H9 human
embryonic stem cell-derived neural progenitors were differentiated
into TrkB-expressing GABAergic inhibitory neurons as described
previously (28–30). As reported, these neurons are electrically active
and develop functional synaptic contacts (28). When differentiated,
these neurons were phase-bright and extended neurites contacting
their neighbors (Fig. 3 A and B). By using immunohistochemical
markers, >90% of the cells expressed the neuronal marker β-III
tubulin (Fig. 3 C and E) and >75% expressed the GABAergic
phenotypic marker glutamate dehydrogenase (GAD65/67; Fig. 3 D
and E). To show that the cells were responsive to BDNF, and thus
expressed TrkB, we stimulated neurons with BDNF (50 ng/mL) and
assessed c-Fos induction at 12 h. Compared with the untreated
control (Fig. 3F), c-Fos immunoreactivity was detected in 75–80%
of neurons treated with BDNF (Fig. 3 G and H). Based on these
observations, the differentiated human neurons described herein
represent a useful model system in which to examine signaling pa-
rameters trigged by ZEB85.
ZEB85 Phosphorylates Human TrkB in a Time- and Concentration-
Dependent Manner. By using the characterized human neuronal
cultures, we tested the ability of the agonist antibody ZEB85 to
stimulate TrkB phosphorylation and compared its signaling
pattern to that of BDNF and NT4 over 24 h. Agonist-stimulated
TrkB phosphorylation was evident throughout the time course
tested (Fig. 4A). Quantitatively, TrkB phosphorylation was ro-
bustly elevated at 30 min and 2 h post treatment with all three
agonists, and declined to near baseline levels at 12 and 24 h (Fig.
4B). Importantly, ZEB85 induced TrkB phosphorylation to the
same extent as BDNF and NT4. To determine the relative po-
tency of each ligand, cultures were treated with a wide concen-
tration range of ZEB85, BDNF, and NT4 for 30 min. Each agonist
showed a concentration-dependent increase in TrkB phosphory-
lation (Fig. 4C). Quantification of six independent experiments
yielded an EC50 for TrkB phosphorylation by ZEB85 of 470 pM
(Fig. 4D), whereas that for BDNF was 190 pM, a value consistent
with its reported EC50 on survival assays using cultured neurons
(32). The EC50 of NT4 in these assays was 1.8 nM, considerably
higher than for BDNF and ZEB85 (Fig. 4D). It is of note that
ZEB30, a full agonist in the TrkB reporter cell assay (Fig. 2A),
stimulated TrkB phosphorylation in hES-derived neurons to the
same extent as ZEB85, BDNF, and NT4; two partial agonists,
ZEB27 and ZEB44, elicited a weaker TrkB phosphorylation re-
sponse, consistent with their partial agonist profile depicted in the
reporter cell.
Effect of TrkB Activation on Transcriptional Regulation in Human
Neurons: Comparison of BDNF, ZEB85, and NT4. To further com-
pare downstream signaling of hES cell-derived neurons when
activated with the three TrkB agonists, we extracted RNA from
neurons treated with ZEB85, BDNF, or NT4 for 30 min or 2, 12,
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Fig. 2. Characterization of the active antibody clones identified from the functional screening. (A) Concentration–response curve of 10 representative active
clones on TrkB reporter cell line. (B) Purified ZEB85 antibody binding to the TrkB reporter cell surface. (C) Representative TrkB agonist clones are not active on
TrkA reporter cell line. (D) Western blot of Trk family ectodomains with two TrkB agonist clones. (E) Time-dependent phosphorylation of TrkB receptor
downstream signaling molecules when stimulated by agonist ligands.
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or 24 h and performed RNA-sequencing (RNA-seq) analyses (SI
Appendix, Methods S1). The top 1,000 shared genes whose ex-
pression was up- or down-regulated by ZEB85, BDNF, or
NT4 across the time course was determined for the four different
time points by using a threshold of an adjusted P value <0.01 and
absolute fold change >2. We observed a striking concordance of
altered levels of gene expression with all three agonist treatments
compared with untreated neurons. At the first time point tested
(30 min), the three TrkB agonists modified expression of a similar
set of 37 genes (Fig. 5A). Eighteen of these genes were immediate-
early response genes and included EGR1, EGR2, EGR3, EGR4,
cFOS, NPAS4, and ARC. This pattern of concordance persisted
throughout the time course for the three ligands. At 2 h post-
treatment, the expression levels of 1,406, 1,389, and 1,403 genes
were altered by BDNF, ZEB85, and NT4, respectively (Fig. 5A),
and 1,044 were common to all three TrkB agonists. At the 12-h
time point, the expression levels of 1,395, 872, and 2,001 genes were
differentially regulated upon treatment with BDNF, ZEB85, and
NT4, respectively (Fig. 5A), and 572 of these genes were common
to treatment with the three agonists. Finally, at 24 h, 947, 337, and
907 genes were differentially expressed by the respective Trk li-
gands. It is interesting to note that >88% of the genes with altered
expression upon exposure to ZEB85 were common to treatment
with BDNF or NT4. However, there was only ∼50% overlap be-
tween the transcriptional changes common to BDNF and NT4.
Analysis of Differentially Expressed Genes. When the differentially
expressed genes were clustered by using a Gene Ontology analysis
of expression in nine different functional categories, a high degree
of similarity was observed for the 12 different experimental con-
ditions in terms of genomewide expression (Fig. 5B). Whereas
comparatively few changes were detected at 30 min, by 2 h, the
changes observed were strikingly similar following treatment with
any one of the three TrkB agonists. After 12- and 24-h treatments,
the transcriptional changes induced by BDNF and NT4 were still
robust, whereas the neurons treated with ZEB85 showed fewer
genes differentially expressed compared with the baseline un-
treated control. Consistent with the proposed neurotrophic role of
TrkB agonists, we observed a two- to fourfold down-regulation of
the proapoptotic gene HRK/DP5 by all three agonists over the 24-h
time course. Likewise, the antiapoptotic genes GADD45A and
CDKN1A (p21) were up-regulated 10–13-fold at 2 h and
remained elevated through the 24-h time course by the three
ligands (SI Appendix, Table S2). Previous reports have shown
that BDNF up-regulates genes important in synaptic function,
such as ARC, SYT2 (synaptotagmin-2), and ACAN (aggrecan)
(33, 34). Consistently, these genes were also up-regulated by
ZEB85 and NT4 to similar levels as with BDNF throughout the
24-h time course (SI Appendix, Table S2).
To validate the results obtained with RNA-seq in Fig. 5A, the
levels of transcriptional regulation exerted by ZEB85, BDNF, and
NT4 on seven of these genes was determined by RT-PCR, and
included the highly up-regulated transcription factors, EGR1,
EGR2, EGR3, and NPAS4, as well as the nerve growth factor-
inducible gene (VGF), synaptic protein (SYNPO), and a phos-
phatase domain protein (PALD1). After 2 h, all of the genes
measured by RT-PCR except PALD1 were up-regulated to higher
levels than observed in the RNA-seq analysis. At 12 and 24 h,
regulation was quantitatively lower as assessed by RT-PCR com-
pared with RNA-seq values (Fig. 5C). Overall, these results cor-
roborate our RNA-seq data and validate the extensive translational
regulation that TrkB agonists, including the antibody ZEB85, exert
upon human neurons.
Characterization of ZEB85 on Rodent Neurons. Whereas the protein
sequence of mature BDNF is identical in all mammals sequenced
thus far, small but significant sequence differences have been
identified in the ectodomain of TrkB among mammalian species.
Although such receptor sequence differences have been shown to
be irrelevant to the cross-species potency of BDNF, these differ-
ences may result in cross-species differences in potency of TrkB
agonist antibodies. To enable appropriate efficacy studies of
ZEB85 in animal models of neurodegenerative disorders, we were
interested to determine the relative potency of ZEB85 on rodent
neurons compared with BDNF. We thus examined the effect of
ZEB85 on TrkB phosphorylation in cultures of mouse cortical
neurons and its effect on axotomized adult mouse retinal ganglion
cells (RGCs) in explant cultures. ZEB85 stimulated TrkB phos-
phorylation in cultured mouse cortical neurons, albeit with lower
potency compared with BDNF (Fig. 6A). To compare the ability of
TrkB agonist antibodies to stimulate dendritic outgrowth in an
intact neuronal network, adult mouse retinal explants were cul-
tured in the presence of BDNF, ZEB85, or ZEB44. After 3 d,
RGCs in explants were labeled with DiI/DiO, counterstained with
DAPI, and imaged by confocal microscopy. Fig. 6B demonstrates
the typical dendritic arbor pattern of RGCs in retinae treated with
vehicle, TrkB agonist antibodies, or BDNF. Sholl analysis (Fig. 6
C–E) revealed a significant increase in dendrite intersections, area
under the curve (AUC), and total dendrite length for BDNF as
previously reported (35). ZEB85 (50 μg/mL) also significantly im-
proved Sholl analysis parameters, albeit with less efficacy and po-
tency than 100 ng/mL of BDNF. ZEB44 (50 μg/mL) resulted in a
modest but significant increase in Sholl AUC and dendritic length,
consistent with its partial agonist profile in the reporter cell assay.
Discussion
The therapeutic potential of neurotrophic factors to treat neu-
rological disorders has been assessed in more than 20 clinical
trials targeting motor neuron disorders, Parkinson’s disease,
Alzheimer’s disease, and peripheral neuropathies, disappoint-
ingly for the most part, with little or no clinical benefit (36).
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Fig. 3. H9 hES cells differentiate as a monolayer of inhibitory neurons that
are highly responsive to BDNF. (A and B) Phase-contrast microscopy of 30 DIV
(days in vitro) neurons. (C) Immunocytochemistry of 30 DIV neurons stained
with β-ΙΙΙ tubulin and DAPI. (D) Immunocytochemistry of 30 DIV neurons with
GAD65/67 and DAPI. (E) Quantification of C and D. Values are mean ± SD of
three independent experiments. (F and G) The 30 DIV neurons were un-
treated (F) or treated with 50 ng/mL BDNF (G) for 12 h and subsequently
fixed and immunostained with DAPI or c-Fos antibody. Quantification is
shown in H. Values are mean ± SD of two independent experiments.
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Among several obstacles that may have stymied these trials were
poorly understood pharmacokinetics, limited pharmacodynamic
markers, suboptimal biophysical properties, and unexpected
clinical side effects of some of these biologic drug candidates.
Whereas a clinical trial testing efficacy of systemically delivered
BDNF in ∼1,000 patients with ALS over 3 y raised no safety
concerns, the unfavorable physiochemical properties and short
t1/2 of recombinant BDNF were most likely the major causes of
failure to show clinically meaningful efficacy. As a highly charged
homodimer, BDNF does not readily penetrate the blood–brain
barrier (37), and therefore several alternative strategies have been
undertaken to activate TrkB signaling within the CNS. These
strategies include the search for small molecules that up-regulate
BDNF expression (18) or those that activate TrkB directly. Al-
though there have been multiple reports on the discovery of small-
molecule TrkB agonists, recent comprehensive surveys using a
wide range of assay systems failed to confirm that any of these
agents activate TrkB in a manner consistent with TrkB phos-
phorylation and canonical signal transduction characteristics of
BDNF (17, 21). Although not a direct resolution of the possible
issue of limited blood–brain barrier penetration, TrkB agonist
antibodies may be an attractive alternative to BDNF for certain
therapeutic indications. Several such antibodies have already been
reported and convincingly shown to activate TrkB in reporter
systems or in neurons derived from induced pluripotent cells (16,
22, 38). By using human neurons derived from embryonic stem
cells grown under conditions favoring the development of TrkB-
responsive neurons, we report here on the detailed characteriza-
tion of a TrkB activating antibody. We propose that the fully hu-
man TrkB agonist antibodies described here may help circumvent
the poor drug-like qualities encountered with BDNF and allow
us to revisit the therapeutic potential of TrkB agonists in certain
neurological diseases.
The majority of clinically approved antibody drugs are an-
tagonists that block specific receptors, such as the case for HER-
2/EGF receptors (39, 40), or sequester specific proteins, as in the
case of anti-TNF or anti-VEGF antibodies (41, 42). Conversely,
among the vast chemical diversity represented by the human an-
tibody repertoire, it is possible to identify antibodies that activate
cell-surface receptors or ion channels. Such agonist antibodies are
rare and thus harder to identify than blocking or neutralizing an-
tibodies. Conventional mouse immunization/hybridoma technology
or in vitro phage display combinatorial antibody technologies are
effectively designed to select high-affinity binders to a target pro-
tein. Although activating antibodies may be among those binders,
in practice, it has required technically demanding, low-throughput,
low-yield secondary assays to identify and optimize any such ago-
nists. To greatly increase the probability of finding such rare ago-
nist antibodies, we have employed a previously described high-
capacity function-based target receptor reporter cell system that
facilitates the selection of agonist antibodies from combinatorial
human antibody libraries with a large diversity (26, 27). Here, we
have described an application of this technology to select agonist
antibodies of a receptor tyrosine kinase, the BDNF receptor TrkB.
In this study, we identified ∼50 agonist antibodies among a library
of ∼10 billion scFv antibody fragments, illustrating the power of the
technology to select rare events. Among these, we found a series of
molecules with full and partial agonist activities toward TrkB and
potencies in the picomolar to nanomolar range. Thus, in addition
to the discovery of candidate therapeutic antibodies, our repertoire
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Fig. 4. Effect of ZEB85, BDNF, and NT4 on TrkB phosphorylation by 30 DIV H9 neurons. (A) Representative immunoblot of the time course of TrkB phos-
phorylation. Cultures were treated with 50 ng/mL BDNF, 5 μg/mL ZEB85, or 75 ng/mL NT4 at the indicated time points. Cell lysates were subjected to Western
blot analyses for phospho-TrkB or synaptophysin (used as loading control) as indicated in Materials and Methods. (B) Densitometric values (mean ± SE)
quantified from the blots of six independent differentiation experiments. (C) Representative blots of the concentration response of TrkB phosphorylation.
Cultures were treated with the indicated concentrations of ZEB85, BDNF, or NT4 for 30 min and then subjected to Western blot analysis. (D) Densitometric
values (mean ± SE) quantified from the blots of six independent differentiations experiments.
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of TrkB agonist antibodies are likely to provide interesting tools to
further dissect signal transduction pathways and biological re-
sponses affected by TrkB stimulation (43).
We chose to perform an in-depth characterization of one an-
tibody, ZEB85, to compare its agonist properties to the cognate
TrkB ligands, BDNF and NT4. Several lines of evidence suggest
that ZEB85 is a potent, full agonist of human TrkB. First, con-
centration–response experiments in our sensitive TrkB reporter
cell line (Fig. 2A) show that the maximal response to ZEB85 is
approximately equal to that of BDNF and NT4 (see also Fig. 1B).
Also, in the hES cell-derived neuronal cells, the Emax for TrkB
phosphorylation was the same for ZEB85 compared with BDNF
and NT4 (Fig. 4 B and D). As with Emax values, the potency of
ZEB85 was similar to that of BDNF in the reporter cell line and
neuronal cells, with EC50 values for BDNF in the 190–300 pM
range and ∼500 pM in both cell types for ZEB85. These intrinsic
potency values for BDNF are consistent with its reported EC50 on
survival assays in cultured neurons (32). Second, agonist-induced
levels of PLCγ, AKT, and ERK phosphorylation by ZEB85 in the
reporter cell line are nearly identical to those of BDNF across
time (Fig. 2E). Conversely, ZEB27 elicited submaximal canonical
phosphorylation signaling, commensurate with its partial activity
C
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(∼20% of BDNF) observed in the reporter cell line assay. Third,
and perhaps most striking, RNA-seq analyses on human neuron-
like cells showed that the numbers and subsets of genes tran-
scriptionally regulated by all three TrkB ligands were qualitatively
similar over a 24-h time course when each agonist was applied as a
single pulse. Quantitative algorithms and statistical analyses of
gene expression changes greater than twofold revealed that the
changes observed in gene expression were common to all three
ligands at 30 min. This overlap was even more evident at 2 and 12 h
post ligand addition, corroborating the like nature of ZEB85 and
BDNF as TrkB agonists. It remains possible that the rates of
ZEB85 application may reveal differences in TrkB signaling com-
pared with BDNF (44), and this will be an important consideration
for dosing regimens in future rodent efficacy studies.
Compared with activity on human TrkB in our reporter cell or in
cultures of human neurons derived from hES cells, ZEB85 showed
weaker effects toward rodent neurons in terms of TrkB phosphor-
ylation on cultures of embryonic rat cortical neurons (Fig. 6A) or in
preservation of the dendritic arbors of RGCs in explant cultures of
adult mouse retina (Fig. 6 B–E). This is not surprising, given that the
human TrkB receptor was used for phage panning and reporter cell
selection and there are sequence differences in the extracellular
domains of human vs. rat TrkB. With the ultimate objective of
evaluating a TrkB agonist antibody for future clinical development,
our primary focus has been to determine the extent of equivalency
of binding potency, TrkB phosphorylation, downstream signaling
cascades, and transcriptional activation of ZEB85 compared with
BDNF in human neurons.
Quantitative PCR analyses of the most highly up-regulated
genes showed that the well-annotated ERG gene family, tran-
scription factors known to be regulated by the neurotrophins, was
coordinately regulated by all three TrkB agonists with a similar
time course and magnitude. Similarly, TrkB agonists increased the
expression of ARC at 30 min (15-fold), peaking at 2 h (25-fold).
BDNF has been shown to regulate ERG3 through activation of
the protein kinase C pathway (45), and ERG3 transcriptional ac-
tivity induces the expression of ARC (46), a protein involved in
synaptic plasticity and long-term potentiation (47). In terms of
synaptic function, ZEB85, BDNF, and NT4 treatment of neurons
also induced expression of SYT2 (synaptotagmin-2), a Ca2+-sens-
ing synaptic protein important for neurotransmitter release in
striatal neurons (48). All three TrkB agonists tested also induced
expression of ACAN (aggrecan; 60-fold at 2 h), an ECM protein
critical in formation of perineural nets linked to maintenance of
synapse integrity and neuroprotection (49). Additionally, ZEB85,
BDNF, and NT4 down-regulated the proapoptotic gene HRK/
DP5, which is known to be induced in neurons following neuro-
trophin deprivation (50), and up-regulated GADD45A and
CDKN1A (p21), genes in pathways with known antiapoptotic,
neuroprotective, and neurogenesis-related functions (51–54).
These observations are consistent with the proposed neurotrophic
role (55) and synaptic function of TrkB agonists and set the stage
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Fig. 6. TrkB phosphorylation in cultured mouse cortical neurons and dendritic outgrowth in mouse retinal explants by TrkB agonists. (A) Phospho-TrkB
Western blot of cultured mouse cortical neurons after addition of BDNF (Left) and ZEB85 (Right). Embryonic day 21 mouse cortical neurons were cultured for
7 d. BDNF (100 ng/mL) or ZEB85 (50 μg/mL) was added, and cultures were harvested at 15–240 min and assayed for phospho-TrkB (arrow) by Western blot.
Molecular weight markers are on the right. (B) Dendritic field analysis of RGCs in retinal explants after 3 d of treatment with ZEB44, ZEB85, BDNF, or vehicle
(control). Neurons were labeled by DiI/DiO DiOlistics. Arrows indicate RGC axons. (Scale bars: 100 μm.) (C) Sholl analysis of dendritic fields of RGCs after TrkB
agonist antibody or BDNF treatment. Numbers of RGCs are indicated. +P < 0.05, ZEB44 vs. vehicle (control); #P < 0.05 and ###P < 0.001, ZEB85 vs. vehicle; *P <
0.05, **P < 0.01, and ***P < 0.001, BDNF vs. vehicle, Kruskal–Wallis test. (D) AUC analysis of Sholl plots and (E) quantification of total dendrite length after
various agonist treatments. *P < 0.05, **P < 0.01, and ***P < 0.005 vs. vehicle, ANOVA, Tukey post hoc test.
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to examine the neuroprotective and neurorestorative effects of
the full agonist ZEB85 in conditions of neuronal stress and
neurodegeneration.
Derivation of mouse monoclonal TrkB agonist antibodies by
conventional immunization techniques has previously been repor-
ted, demonstrating that it is possible to identify such agonists by
standard hybridoma approaches. Qian et al. (23) identified mouse
monoclonal antibody 29D7 and showed that it cross-reacted with
human TrkB in stimulating receptor phosphorylation in a human
TrkB reporter cell line and exhibited typical canonical signaling in
these cells, with activities in the 100-pM range. The antibody also
increased neurite outgrowth and survival of differentiated SH-
SY5Y human neuroblastoma cells. A humanized version of this
antibody, TAM-163, was derived and shown to be a partial agonist
in human TrkB reporter cells with an EC50 of ∼1 nM. This anti-
body decreased body weight in mice but possessed the opposite
effect in nonhuman primates (56). As with our antibody ZEB85,
neither of these antibodies bound to p75.
In addition, a further mouse monoclonal TrkB agonist antibody,
38B8, has been reported to show agonist activity toward mouse
and human TrkB in reporter cell lines and efficacy in models of
obesity and metabolic disease (57). Traub et al. (38) have reported
the generation of two humanized TrkB agonist antibodies (AB2
and AB20) by grafting the complementary determining regions of
two mouse monoclonal antibodies to separate human IgG back-
bones and characterized these antibodies on TrkB reporter cells
and iPS-derived neurons (GRINCH neurons). The EC50 values
for BDNF were 540 pM in their reporter cell line and 25 pM in
GRINCH neurons. Corresponding values for AB2 were 390 pM
and 67 pM, whereas antibody AB20 showed EC50 values of
404 pM in the reporter cell line and 80 pM in GRINCH neurons.
In these studies, RNA-seq was also performed in the GRINCH
neurons treated with BDNF and agonist antibodies for 6 h. In
contrast to our observation of extensive transcriptional regulation
of many hundreds of genes in hES cell-derived neurons treated
with ZEB85, the Traub et al. study reported changes in mRNA
levels (greater than the twofold threshold) in less than 50 genes.
Possible explanations for the quantitative discrepancy may lie in
the different cell types used in the two studies—iPSCs vs. ES cells—
and differences in the differentiation protocols to generate
neurons. Further, the hES cell neurons derived in the present
study were shown to be highly enriched for the GABAergic phe-
notype (>75%) and also expressed functional TrkB as shown by c-
Fos induction with BDNF or ZEB85. Conversely, the GRINCH
neuron-like cultures derived by Traub et al. (58) have been shown
to express a variety of different neurotransmitter phenotypes. The
percentage of cells responding to BDNF in these cultures was not
reported (59, 60).
In summary, we have demonstrated that a function-based re-
porter cell system can be employed effectively to screen combi-
natorial antibody libraries to select agonist (i.e., activating)
antibodies for the receptor tyrosine kinase, TrkB, the cognate
receptor for the neurotrophic factor BDNF. Although we have
presented detailed characterization of one such antibody, ZEB85,
the methodology yields an interesting array of antibodies over the
range of full and partial agonists. Our approach may have several
benefits in the search for potentially therapeutic biologic drugs.
Most notably, a TrkB agonist antibody circumvents the biophysical
and pharmacokinetic pitfalls of BDNF. Also, antibodies offer
flexibility of format in terms of delivery to different compartments,
including systemic or localized injections to improve t1/2. Finally,
an agonist antibody has the potential to overcome immunogenicity
that has been problematic with several recombinant human
growth factors. Although, initially, almost all human recombinant
proteins generate a transient immune response when administered
to humans, the majority of such initial responses do not lead to the
generation of neutralizing antibodies. However, in the case of
ciliary neurotrophic factor and thrombopoietin, s.c. injections of
recombinant human versions of these small proteins induced
neutralizing antibodies in patients, resulting in the termination of
clinical trials. Thus, a fully human agonist antibody may circum-
vent this issue. We conclude that the use of our function-based
screening approach successfully selected multiple rare TrkB ago-
nist antibodies and may serve as a template to aid the selection of
agonist antibodies to other receptor tyrosine kinases.
Materials and Methods
Detailed descriptions of study materials and methods are provided in SI
Appendix, Methods S1, including all reagents and protocols for phage pan-
ning and lentivirus preparation; reporter-based functional selection, expres-
sion, purification, and characterization of scFv–Fc fusion proteins; molecular
biology reagents; hES cell neural differentiation; construction of cDNA libraries
and RNA-seq, quantitative RT-PCR, cell lysis, and protein extraction; Western
blotting; immunofluorescence; mouse cortical neuron cultures; and mouse
retinal explants.
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